Briefing
Molecular residual disease assessment in early-stage breast cancer
Interventional study of postoperative ctDNA in lymph-node-positive early breast cancer. The registry lists the phase as not applicable and the primary outcome as the number of participants with postoperative ctDNA detected. ClinicalTrials.gov lists the study as recruiting.
- Design: Not applicable · Recruiting